Prospective Trial for the Treatment of Malignant Peritoneal Mesothelioma
Authors:
- 1 October 2001
- journal article
- clinical trial
- Published by SAGE Publications in The American Surgeon™
- Vol. 67 (10) , 999-1003
Abstract
Malignant peritoneal mesothelioma (MPM) is a rare and often rapidly fatal disease with median survival of 5 to 12 months for untreated cases and 16 months reported after multimodality treatment. We report a prospective clinical treatment study using cytoreductive surgery combined with intraoperative intraperitoneal heated chemotherapy (IPHC) perfusion using mitomycin C for MPM. Twelve patients (11 male with a mean age 51 years) were treated. Seven patients presented with bulky disease and seven with ascites. All underwent exploratory laparotomy with histologically confirmed diagnosis of MPM. Surgical debulking as feasible was performed. Complete gross tumor removal was possible in only one patient. Cytoreduction was followed by a 2-hour closed low-volume IPHC using mitomycin C. One patient died 50 days postoperatively from complications relating to small bowel perforation. Hematologic toxicity of the procedure was minimal. Ascites was controlled in all patients and permanently in 86 per cent of patients presenting with ascites. To date median survival is 34.2 months with median follow-up of 45.2 months. One patient was re-explored for ventral hernia 2 years post-IPHC, had negative peritoneal biopsies, and remains disease-free at 5 years. Given the dismal prognosis associated with MPM the results of treatment with cytoreductive surgery combined with IPHC perfusion are encouraging. The rarity of MPM makes appropriately powered prospective randomized trials unlikely. Therefore, we now offer this approach off protocol; however, further study of this combined modality therapy is warranted.Keywords
This publication has 13 references indexed in Scilit:
- Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosisEuropean Journal of Surgical Oncology, 2001
- Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Disseminated Peritoneal Cancer of Gastrointestinal OriginThe American Surgeon™, 2000
- Interaction between gemcitabine and mitomycin-C in vitroCancer Chemotherapy and Pharmacology, 2000
- Treatment of Primary Peritoneal Mesothelioma by Continuous Hyperthermic Peritoneal Perfusion (CHPP)Annals of Surgical Oncology, 1999
- Treatment of primary peritoneal mesothelioma by hyperthemic intraperitoneal chemotherapyPerfusion, 1999
- Effectiveness of 2',2'difluorodeoxycytidine (Gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivoInternational Journal of Hyperthermia, 1999
- Impressive remission in a patient with locally advanced malignant pleural mesothelioma treated with gemcitabineAnti-Cancer Drugs, 1999
- Complications of heated intraperitioneal chemotherapy and strategies for prevention1996
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958